OR WAIT null SECS
May 16, 2024
The CDMO’s latest business venture reaffirms its commitment to the development of novel radiopharmaceuticals.
May 15, 2024
The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.
May 14, 2024
The development project adds an additional 157,500 square feet to the existing facility in the process.
May 09, 2024
The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.
April 29, 2024
The CDMO’s boost in production will be centered around pharmaceutical products.
April 25, 2024
The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
April 09, 2024
The acquisition initiates a long-term agreement with Beacon Therapeutics, highlighted by clinical and commercial AAV production.
March 22, 2024
The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.
March 08, 2024
A proposed Senate bill is intended to protect citizens’ private health and genetic information.